New Mexico Educational Retirement Board Has $3.92 Million Stake in Vertex Pharmaceuticals Incorporated (VRTX)

Share on StockTwits

New Mexico Educational Retirement Board cut its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.3% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 21,300 shares of the pharmaceutical company’s stock after selling 500 shares during the period. New Mexico Educational Retirement Board’s holdings in Vertex Pharmaceuticals were worth $3,918,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Parallel Advisors LLC lifted its stake in Vertex Pharmaceuticals by 5.8% in the 4th quarter. Parallel Advisors LLC now owns 1,091 shares of the pharmaceutical company’s stock valued at $180,000 after buying an additional 60 shares in the last quarter. Kovack Advisors Inc. lifted its stake in Vertex Pharmaceuticals by 4.2% in the 4th quarter. Kovack Advisors Inc. now owns 1,484 shares of the pharmaceutical company’s stock valued at $246,000 after buying an additional 60 shares in the last quarter. Grandfield & Dodd LLC lifted its stake in Vertex Pharmaceuticals by 1.0% in the 4th quarter. Grandfield & Dodd LLC now owns 6,239 shares of the pharmaceutical company’s stock worth $1,034,000 after purchasing an additional 61 shares in the last quarter. ETRADE Capital Management LLC lifted its stake in Vertex Pharmaceuticals by 0.5% in the 4th quarter. ETRADE Capital Management LLC now owns 11,897 shares of the pharmaceutical company’s stock worth $1,972,000 after purchasing an additional 65 shares in the last quarter. Finally, Impax Asset Management Group plc lifted its stake in Vertex Pharmaceuticals by 1.9% in the 4th quarter. Impax Asset Management Group plc now owns 3,467 shares of the pharmaceutical company’s stock worth $575,000 after purchasing an additional 66 shares in the last quarter. Hedge funds and other institutional investors own 95.37% of the company’s stock.

Several analysts have recently commented on the stock. Zacks Investment Research raised shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, January 26th. BidaskClub raised shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, January 10th. BMO Capital Markets lifted their price target on shares of Vertex Pharmaceuticals to $234.00 and gave the company an “outperform” rating in a research report on Wednesday, February 6th. Cowen reaffirmed a “buy” rating and set a $220.00 price target on shares of Vertex Pharmaceuticals in a research report on Wednesday, March 6th. Finally, Maxim Group reaffirmed a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Wednesday, March 6th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $203.31.

In other Vertex Pharmaceuticals news, SVP Paul M. Silva sold 2,812 shares of the business’s stock in a transaction on Tuesday, February 19th. The shares were sold at an average price of $186.97, for a total value of $525,759.64. Following the completion of the transaction, the senior vice president now owns 18,903 shares in the company, valued at $3,534,293.91. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Jeffrey M. Leiden sold 32,250 shares of Vertex Pharmaceuticals stock in a transaction on Monday, February 4th. The stock was sold at an average price of $186.35, for a total transaction of $6,009,787.50. Following the sale, the chief executive officer now directly owns 155,815 shares of the company’s stock, valued at $29,036,125.25. The disclosure for this sale can be found here. Insiders sold a total of 208,624 shares of company stock valued at $38,187,166 in the last quarter. 0.75% of the stock is owned by insiders.

Vertex Pharmaceuticals stock opened at $179.82 on Wednesday. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $144.07 and a fifty-two week high of $195.81. The company has a market capitalization of $45.95 billion, a P/E ratio of 63.54, a P/E/G ratio of 2.67 and a beta of 1.64.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Tuesday, February 5th. The pharmaceutical company reported $1.30 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.06 by $0.24. Vertex Pharmaceuticals had a net margin of 68.81% and a return on equity of 24.15%. The firm had revenue of $870.11 million during the quarter, compared to the consensus estimate of $818.29 million. During the same quarter last year, the firm earned $0.61 EPS. The firm’s revenue for the quarter was up 33.5% on a year-over-year basis. Equities analysts expect that Vertex Pharmaceuticals Incorporated will post 3.04 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “New Mexico Educational Retirement Board Has $3.92 Million Stake in Vertex Pharmaceuticals Incorporated (VRTX)” was originally posted by BBNS and is owned by of BBNS. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at https://baseballnewssource.com/2019/04/17/new-mexico-educational-retirement-board-has-3-92-million-stake-in-vertex-pharmaceuticals-incorporated-vrtx/3359196.html.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.

Further Reading: Trading Strategy

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.